P2.09-09 A Phase 1, 2 Study to Evaluate the Safety and Anti-tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced NSCLC

EGFR mutations are the most common driver mutations in NSCLC. While EGFR tyrosine kinase inhibitors (TKIs) are the recommended front-line option for EGFR-mutant advanced NSCLC patients, these patients invariably develop acquired resistance and face disease progression. JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, including C797S mutation that causes resistance to Osimertinib. In preclinical studies, JIN-A02 has demonstrated activity as a monotherapy in models with EGFR mutations that are resistant to Osimertinib.